Business Highlights

Itay&biond develops a drug discovery platform to establish the next generation of treatments for Autism Spectrum Disorders and other Psychiatric and Neurological Dysfunctions.

These compounds will be going through a unique and patented estimation of their clinical efficacy using the novel technology that underlies our drug discovery platform. The most promising compounds will go on for pre-clinical study. 

Our business opportunities include licensing, co-development, and sells of drugs developed up to pre-IND.

 

Company Profile

About

  • Established in 2021, Itay&Biond is an innovative company that develops a drug discovery platform for the treatment of Autism Spectrum Disorders (ASD).

Management Team

  • Itay&Biond is led by a strong and experienced team of professionals and scientists with expert know-how and experience in the biologics pharma industry.

Technology Innovation

  • Itay&Biond delivers an innovative, scalable and cost-effective biologics model based on AI-driven predictive analytics and advanced biotechnology methods.

Partnerships

  • Together With Hadassah Hospital In Jerusalem, We Are Currently Validating Our Drug Discovery Platform Using Samples Of 200 Patients.

Intellectual Property

  • Itay&Biond holds two issued US patents with PCT extensions. Additional patent applications are in process.

Investment Opportunity

  • Our biologics drug discovery platform has the potential to treat ASD in addition to a wide range of previously untreatable diseases.

Company Achievements

Company Formation

Proof of concept

Promising preliminary results of the RNA-based molecule for treating sub-population of Autism spectrum disorders

IP submission

RNA-based molecule for treating sub-population of Autism spectrum disorders

IP submission

Novel scalable non-invasive sample collection device

Helsinki Approval

200 samples of ASD patients

Start of Clinical Trial

Hadassah Hospital

Patient-derived brain organoids

Growing hundred of ASD patients brain organoids

V1 prototype

Scalable drug screening and discovery platform

Next milestones

2022

2022

Testing our first RNA-based drug for a defined sub-population of ASD on our patient-based samples

2023

2023

Technology scale-up
Compound screening for new targets

2024

2024

Systematic screening and development of new treatments for ASD based on personal brain organoid formation
en_USEnglish
Skip to content